Literature DB >> 2670213

Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

M Sznol1, J P Dutcher, M B Atkins, A R Rayner, K A Margolin, E R Gaynor, G R Weiss, F Aronson, D R Parkinson, M J Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2670213     DOI： 10.1016/0305-7372(89)90020-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

1.  Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model.

Authors:  Charles F Babbs
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

2.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

3.  Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

Authors:  D V Spicer; A Kelley; R Herman; G Dean; L Stevenson; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

5.  Progress and controversies in developing cancer vaccines.

Authors:  Craig L Slingluff; Daniel E Speiser
Journal:  J Transl Med       Date:  2005-04-29       Impact factor: 5.531

Review 6.  Anatomy of a discovery: m1 and m2 macrophages.

Authors:  Charles Dudley Mills
Journal:  Front Immunol       Date:  2015-05-05       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.